Humana (HUM) Stock Price, News & Analysis

Company Overview

Humana Inc. is a health and well-being company that provides insurance products and health care services in the United States and Puerto Rico. The company’s primary business is government-sponsored health coverage, particularly Medicare Advantage plans for older adults, along with Medicare prescription drug plans, Medicaid coverage and certain commercial health insurance products.

Humana also operates CenterWell, its health care services platform focused on older adults. CenterWell includes primary care clinics, home health services and pharmacy services, with an emphasis on coordinated care, chronic-condition management and helping members receive care in lower-cost settings.

Founded in 1961 as a nursing-home company, Humana expanded into hospital operations before shifting its focus toward health insurance and related services. The company is headquartered in Louisville, Kentucky. Jim Rechtin serves as Humana’s president and chief executive officer.

Key Stats

• Today's Range: $415.26 to $430.15
• 50-Day Range: $371.93 to $432.24
• 52-Week Range: $163.11 to $456.50
• Volume: 1.30 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $50.02 billion
• P/E Ratio: 39.41
• Dividend Yield: 0.85%
• Price Target: $453.30
• Consensus Rating: Moderate Buy

Humana Stock Analysis - MarketRank™

Humana scored higher than 74% of companies evaluated by MarketBeat, and ranked 95th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Humana has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 21 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Humana is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Humana has been the subject of 24 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 77.41%

Earnings Growth

Earnings for Humana are expected to grow by 77.41% in the coming year, from $9.03 to $16.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humana is 39.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.13.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humana is 39.41, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.99.

Price to Earnings Growth Ratio

Humana has a PEG Ratio of 2.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Humana has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.06% of the float of Humana has been sold short.

Short Interest Ratio / Days to Cover

Humana has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Humana has recently increased by 31.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Humana has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Humana does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Humana is 33.49%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Humana will have a dividend payout ratio of 22.10% next year. This indicates that Humana will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Humana has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Humana this week, compared to 10 articles on an average week.

Search Interest

27 people have searched for HUM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

6 people have added Humana to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Humana insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.20% of the stock of Humana is held by insiders.

Percentage Held by Institutions

92.38% of the stock of Humana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 7/31 Dividend: 6/26/2026
• Ex-Dividend for 7/31 Dividend: 6/26/2026
• Last Earnings: 7/29/2026
• Dividend Payable: 7/31/2026
• Today: 10/27/2026
• Record date for 11/27 Dividend: 10/30/2026
• Ex-Dividend for 11/27 Dividend: 10/30/2026
• Next Earnings (Estimated): 11/06/2026
• Dividend Payable: 11/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Managed Healthcare
• Current Symbol: NYSE:HUM
• CIK: 49071
• Web: www.humana.com
• Phone: (502) 580-1000
• Fax: 502-580-3639
• Employees: 67,060
• Year Founded: 1961

Price Target and Rating

• Average Price Target for Humana: $453.30
• High Price Target: $596.00
• Low Price Target: $195.00
• Potential Upside/Downside: +8.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 32 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.57
• Trailing P/E Ratio: 39.41
• Forward P/E Ratio: 46.13
• P/E Growth: 2.6
• Net Income: $1.19 billion
• Net Margins: 0.88%
• Pretax Margin: 1.15%
• Return on Equity: 11.20%
• Return on Assets: 3.94%

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 1.74
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: $145.68 billion
• Price / Sales: 0.34
• Cash Flow: $23.75 per share
• Price / Cash Flow: 17.54
• Book Value: $147.47 per share
• Price / Book: 2.82

Miscellaneous

• Outstanding Shares: 120,080,000
• Free Float: 119,840,000
• Market Cap: $50.02 billion
• Optionable: Optionable
• Beta: 0.74